Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. (March 2022)

• Record Type: Journal Article
• Authors: Bartoli, Francesco; Cavaleri, Daniele; Callovini, Tommaso; Riboldi, Ilaria; Crocamo, Cristina; D'Agostino, Armando; Martinotti, Giovanni; Bertolini, Federico; Ostuzzi, Giovanni; Barbui, Corrado; Carrà, Giuseppe
• Is Part Of: Psychiatry research. Volume 309(2022)
• Publication Date: 2022-03
• Subjects: Long-acting injectable antipsychotics -- Paliperidone palmitate 1-month -- Aripiprazole monohydrate; Psychiatry -- Periodicals; Psychiatry -- periodicals; Psychiatrie -- Périodiques; 616.89
• DOI: 10.1016/j.psychres.2022.114405
• Languages: English
• ISSNs: 0165-1781

Abstract

Highlights: Paliperidone palmitate and aripiprazole monohydrate are frequently prescribed LAIs. We compared their 1-year effectiveness and acceptability. We analysed these outcomes in 195 subjects with schizophrenia. The rates of hospitalization and symptom improvement were comparable. Similarly, discontinuation at one year did not differ. Abstract: In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement ( p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.